Determinants of 6-minute walk test in people with Parkinson’s disease

Kalkan, Aybüke Cansu; Kahraman, Turhan; Çolakoğlu, Berril Dönmez; Çakmur, Raif; Genç, Arzu

doi:10.1007/s11845-022-02954-7

Cited by 4 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of the SVSD on FoG needs to be determined in further studies with more participants. Considering one participant's feedback that wished for a longer wearing duration, the 6 minute Walking Test (6MWT) could be used [ 31 ]. Our population had an average walking speed of 1.4–1.6 m/s compared to Lindholm with 0.9 m/s.…”

Section: Discussionmentioning

confidence: 99%

Exploring a New Cueing Device in People Who Experience Freezing of Gait: Acceptance of a Study Design

Wilhelm

Riedl

Paumann

et al. 2022

Parkinson's Disease

View full text Add to dashboard Cite

Background. Freezing of Gait (FoG) is a disabling symptom of Parkinson’s Disease (PD) and is defined as a “brief episodic absence or marked reduction of forward progression of the feet despite the intention to walk.” Compensatory strategies such as cueing and high frequency vibrotactile stimulation can reduce FoG severity and improve gait parameters. A new Sternal high frequency Vibrotactile Stimulation Device (SVSD) with cueing function has been developed, however the clinical effects of this device are yet to be fully investigated. Objective. The aim of this study was to investigate, if the proposed study design using a SVSD and gait analysis sensor insoles was acceptable for people with PD. Methods. This feasibility study was designed as a randomized cross-over study. Thirteen participants took part in a one off 60-minute data collection session. The acceptability of the study design was assessed with a mixed methods questionnaire considering each step of the study process. Secondary outcome measures were the feasibility of using the 10 Metre Walk Test (10MWT), the Freezing of Gait Score (FoG-Score), and Patient Global Impression of Change (PGI-C) with and without the SVSD. Results. The participants scored all aspects of the study design as very satisfactory. In addition, all participants could perform the secondary outcome measures and were deemed feasible. Feedback from open ended questions provided ideas and considerations for adaptations of future clinical studies. Conclusion. The proposed study design was acceptable for people with PD. Implications. This study design, with small adaptations, can be used for larger studies to evaluate the effect of an SVSD on FoG in people with PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring a New Cueing Device in People Who Experience Freezing of Gait: Acceptance of a Study Design

Wilhelm

Riedl

Paumann

et al. 2022

Parkinson's Disease

View full text Add to dashboard Cite

show abstract

“…x Change in functional capacity evaluated by a 6-min Walking Test (6MWT), a standardized method to assess the maximal patient’s capacity to walk as far as possible (measured in meters) ( 54 );…”

Section: Methods and Analysismentioning

confidence: 99%

Dose–response effects of physical exercise standardized volume on peripheral biomarkers, clinical response, and brain connectivity in Parkinson’s disease: a prospective, observational, cohort study

Rotondo,

Padua,

Annino

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

BackgroundExercise has been proposed as the “Universal Prescription for Parkinson’s Disease”; however, the specificity of exercise dose in terms of frequency, intensity, duration, and type to be prescribed remains to be elucidated. The 2018 US updated guidelines and WHO Guidelines on Physical Activity and Sedentary Behavior recommend older adults (> 65+ years) to achieve weekly minimal activity levels, indicating the intensity of aerobic exercise as the metabolic equivalent of task and duration as minutes/week (150–300 min/week at a moderate intensity of 3–5.9 MET- or 75–150 min/week of a vigorous intensity of ≥6 MET). Translating these recommendations to PD patients, the study aimed to assess the dose–response effects of standardized volume of structured exercise, measured as METs-minutes/week (weekly energy expenditure) of two different rehabilitation settings to quantify the change in neurotrophic factors. The exercise-induced benefits between the two rehabilitation settings will be evaluated based on motor and non-motor symptoms, kinematic parameters of gait, cognitive function, quality of life, and cortical activity and brain connectivity.MethodsMETEX-PD is a pilot, prospective, observational, cohort study. The study will enroll consecutively thirty (N = 30) participants with mild-to-moderate Parkinson’s disease diagnosis to be assigned to a non-intensive or intensive rehabilitation group. The non-intensive rehabilitation group will achieve a range of 180–270 METs-min/week (90 min/week of low-intensity aerobic exercise, 2–3 METs), while the intensive rehabilitation group will exercise at 1350–1980 METs-min/week (225 min/week of high-intensity aerobic exercise, 6–8.8 METs). The METEX-PD trial will last 12 weeks, including 4 weeks of aerobic training program and two follow-ups. Assessments will be performed at baseline (T0), at the end of the exercise program (T1—end of the program), and 4- and 8 weeks after the end of the training program (FU-1 and FU-2). The primary outcome is the change from baseline in peripheral blood BDNF levels. Secondary outcomes are differences in peripheral biomarkers, functional-motor assessments, clinical-functional evaluations, and brain imaging.ConclusionMETEX-PD trial will enable us to estimate the change in BDNF levels and other peripheral biomarkers under precise exercise-induced energy expenditure. The primary results of the METEX-PD study will allow the development of a larger multicenter randomized controlled trial to investigate the molecular pathways inducing the change in selected neurotrophic factors, such as BDNF, IGF-1, or irisin, and the downstream mechanisms of neuroplasticity in PD patients.

show abstract

Real-time auditory feedback for improving gait and walking in people with Parkinson’s disease: a pilot and feasibility trial

Mayo,

Mate,

Fellows

et al. 2024

Pilot Feasibility Stud

View full text Add to dashboard Cite

Determinants of 6-minute walk test in people with Parkinson’s disease

Cited by 4 publications

References 37 publications

Exploring a New Cueing Device in People Who Experience Freezing of Gait: Acceptance of a Study Design

Exploring a New Cueing Device in People Who Experience Freezing of Gait: Acceptance of a Study Design

Dose–response effects of physical exercise standardized volume on peripheral biomarkers, clinical response, and brain connectivity in Parkinson’s disease: a prospective, observational, cohort study

Real-time auditory feedback for improving gait and walking in people with Parkinson’s disease: a pilot and feasibility trial

Contact Info

Product

Resources

About